Effect of polymorphisms of NF-κB and PXR on platinum-based chemotherapy for non-small cell lung cancer.
10.11817/j.issn.1672-7347.2016.03.002
- Author:
Yaxing ZHOU
1
;
Pei YANG
2
;
Yingzhi LIU
1
;
Liansheng WANG
1
Author Information
1. Institute of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008; Institute of Clinical Pharmacology; Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China.
2. Affiliated Hunan Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410014, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Carcinoma, Non-Small-Cell Lung;
Genotype;
Humans;
Lung Neoplasms;
NF-kappa B;
Platinum;
Polymorphism, Genetic;
Pregnane X Receptor;
Receptors, Steroid;
Transcription Factor RelA
- From:
Journal of Central South University(Medical Sciences)
2016;41(3):233-237
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of polymorphisms of NF-κB rs230521, NF-κB rs4648068 and pregnane X receptor (PXR) rs3814058 on platinum-based chemotherapy for non-small cell lung cancer patients.
METHODS:We collected 262 cases of non-small cell lung cancer patients, and then analyzed the genotypes of NF-κB and PXR by MassARRAY method. The impact of polymorphisms on efficacy, gastrointestinal toxicity and hematological toxicity was analyzed by logistic regression.
RESULTS:Compared to patients with GG genotype, patients with NF-κB rs230521 CC genotype had the higher risk to suffer hematological toxicity (OR=3.485, P=0.011). Patients with PXR rs3814058 CC and CT genotype exhibited higher possibility to suffer hematological toxicity than those with TT (OR=2.045, P=0.048). Polymorphism of NF-κB rs4648068 did not show significant effect on chemotherapy efficacy and occurrence of gastrointestinal toxicity and hematological toxicity.
CONCLUSION:Patients with NF-κB rs230521 CC, PXR rs3814058 CC and CT had higher risk to suffer hematological toxicity during platinum-based chemotherapy for non-small cell lung cancer. A rational dosage and course of treatment should be chosen to protect the patients with high risk genotype suffering hematological toxicity during their platinum-based therapy.
